Doxycycline-Induced Liver Injury

Introduction to Hepatotoxicity

The Centers for Disease Control and Prevention (CDC) guidelines note that while fatty liver of pregnancy occurred with high-dose intravenous tetracycline, no reports of maternal hepatic toxicity associated with doxycycline use have been published in that specific population 1

The American Gastroenterological Association, as reported in the journal Gut, suggests that minocycline carries substantially higher hepatotoxic risk than doxycycline, particularly for autoimmune hepatitis and drug-induced lupus with prolonged use 2
The European Association for the Study of the Liver, as reported in the journal Alimentary Pharmacology and Therapeutics, recommends interrupting drug if ALT ≥8× ULN (with or without bilirubin elevation), interrupting drug if ALT ≥3× ULN with total bilirubin ≥2× baseline, and repeating testing within 2-5 days and initiating workup for competing etiologies 3

The CDC emphasizes that for serious tickborne rickettsial diseases, doxycycline remains the treatment of choice despite theoretical concerns, as the benefits of doxycycline treatment clearly outweigh the rare risk of hepatotoxicity 1

Minocycline is associated with a higher risk of autoimmune hepatitis and drug-induced lupus with longer treatment durations, compared to doxycycline 4

Consider alternative antibiotics based on the indication when doxycycline-induced liver injury is suspected 5

Baseline liver function tests may be advisable before initiating doxycycline therapy, especially in patients with pre-existing liver conditions, and monitor liver function tests during treatment, particularly in patients undergoing prolonged therapy 6